November 2015 Analysis

Industry Trend Analysis - Velcade Successor Will Face Tougher Market Environment - NOV 2015

Ixazomib will maintain Takeda Pharmaceutical Company's number one position in the proteasome inhibitor field. If Takeda implements a switching plan and it is executed successfully, ixazomib could match Velcade in terms of value to Takeda. However, the multiple myeloma market is evolving rapidly and competition has increased considerably since the launch of Velcade. Capitalising on first-to-mark...